Indian Prime Minister modi said in a speech on the 15th that “the whole country of India is waiting for the emergence of domestically manufactured vaccines. Three candidate vaccines are now in different stages of testing. Once these vaccines are approved, India will start mass production. ” < / P > < p > from July 24, the first phase of human trials of two indigenous vaccines developed in India began. More than 1000 volunteers participated in the trial. According to the arrangement of the Indian Medical Research Council (ICMR), the phase I and phase II human trials of the two vaccines in India will be conducted in a randomized, double-blind, placebo-controlled clinical trial. The volunteers in the first phase of the trial are all healthy people aged 18-55 years without underlying diseases. The second phase was volunteers aged 12 to 65. Theoretically, the duration of phase III clinical trial is 6-8 months. The observation aspects of the phase III human trials of the vaccine development are different. The main safety indexes were observed in the first stage. Second phase clinical observation of the effectiveness, that is to observe immunogenicity. The third phase of clinical observation is to observe the virus infection rate and protection rate of vaccine in the process of human protection in the epidemic population and region. The protection rate is the key to judge the success of vaccine development. In addition to the first phase trial of two new coronal lung vaccines in India, a third phase trial is being conducted in India for a vaccine developed by Oxford University. Based on the current progress and clinical update, they hope the Oxford vaccine will be available before the end of the year. The Indian Serum Institute (SII), the world’s largest producer of vaccines, said Oxford University and its partner Astra jerichon in the UK said it was ready to commission large-scale vaccine production to the Indian Serum Institute. In the past, vaccines produced in India accounted for 60% of the global market share, according to the head of India’s Medical Research Council. The novel coronavirus pneumonia vaccine is being developed in various countries around the world. In view of this, India’s vaccine research and development must race against the clock, in line with the requirements of science, quality and ethics, and strive to accelerate the research and development of local vaccines.